ES Journal - 2019/2020

Status
Not open for further replies.
The "virus" news came out the exact same time as worse than expected gdp. You think that's just a coincidence? lol
Gilead is shady as fuck. There are many companies working on a vaccine at the moment, but you don't hear anything about them. Most likely GILD is not doing any better than their "competition", they just report a lot of hope and investors buy it.
 
The market is so funny. I actually thing the GDP number is "bullish" The Fed put will just remain in play.

EDIT: I'm building put option positions as an insurance for my long positions.
 
Good to have you back, Schizo.

It's not paranoia if they're after you, and in the market they are.

That's why I don't like posting my stops. In fact, I only post some trades out of "politeness" and respect for those who usually do.

---

LF, we're not going to have a repeat of yesterday's PA, right?
 
Gilead is shady as fuck. There are many companies working on a vaccine at the moment, but you don't hear anything about them. Most likely GILD is not doing any better than their "competition", they just report a lot of hope and investors buy it.
Remdesivir of GILD is an anti-viral treatment, not vaccine. Their phase III trial could be done within weeks on fast-track approval. GILD has no competition at all for this drug. But none of their announcement so far mentioned anything about comparison to the control group (placebo), therefore meaningless.

However, vccine development at MRNA, INO, BNTX ... are more risky bets than GILD. Most of them have less than 10% of chance and the time frame could be as long as 3-5 years.
 
Remdesivir of GILD is an anti-viral treatment, not vaccine. Their phase III trial could be done within weeks on fast-track approval. But none of their announcement so far mentioned anything about comparison to the control group (placebo), therefore meaningless.

However, vccine development at MRNA, INO, BNTX ... are more risky bets than GILD. Most of them have less than 10% of chance and the time frame could be as long as 3-5 years.


The NIAID study is a double blind, placebo-controlled study. It's being reported that it met its primary end-point.
 
Status
Not open for further replies.
Back
Top